{{Rsnum
|rsid=4072520
|Gene=GSK3B
|Chromosome=3
|position=119916546
|Orientation=plus
|GMAF=0.2484
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=GSK3B
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 3.5 | 38.9 | 57.5
| HCB | 0.0 | 12.4 | 87.6
| JPT | 0.9 | 15.9 | 83.2
| YRI | 34.2 | 51.4 | 14.4
| ASW | 26.3 | 45.6 | 28.1
| CHB | 0.0 | 12.4 | 87.6
| CHD | 0.9 | 13.8 | 85.3
| GIH | 4.0 | 38.6 | 57.4
| LWK | 31.8 | 50.0 | 18.2
| MEX | 1.7 | 32.8 | 65.5
| MKK | 14.1 | 46.2 | 39.7
| TSI | 2.9 | 45.1 | 52.0
| HapMapRevision=28
}}
{{PMID|18500637}} [[rs7624540]], [[rs4072520]], [[rs6779828]] showed genotypic association with [[schizophrenia]]

{{PMID Auto
|PMID=20605420
|Title=Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
}}

{{PMID Auto
|PMID=18676680
|Title=Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}